Stake saleHealthcare & Life Sciences
API Holdings sells Thyrocare stake, repays debt
By Abha Lohia · Editor ·
PharmEasy: funding and every story →
Navi MumbaiFounded 2019
- API Holdings runs PharmEasy, an online pharmacy, and Thyrocare, a diagnostics chain
- Its subsidiary Docon sold 9.9% of Thyrocare for ₹986 crore, used to repay ₹1,050 crore debt
- The company is now debt-free and expects PharmEasy to turn profitable within 3-4 quarters
What happened
- API Holdings, the parent of PharmEasy and Thyrocare, repaid ₹1,050 crore of debt and became debt-free.
- Its subsidiary Docon Technologies sold 1.57 crore Thyrocare shares (9.9% stake) on 13 August 2026 for ~₹986 crore.
- The block deal was executed at ₹624 per share, a ~3% discount to the previous close.
- Buyers included Citigroup, Morgan Stanley, and HSBC Mutual Fund.
- Thyrocare stock fell ~8% intraday on 13 August after the stake sale.
- Earlier, Docon sold ~10% of Thyrocare in October 2025 for ~₹668 crore.
- The two stake sales together raised ~₹1,650 crore for API Holdings.
- After the sale, promoter holding in Thyrocare dropped from 60.92% to 51.02%.
Why it matters
- API Holdings had borrowed ₹2,280 crore from Goldman Sachs in 2022 at 17-18% interest to refinance the Thyrocare acquisition debt.
- In 2023, it breached a loan covenant after failing to raise ~₹1,000 crore in equity.
- The debt repayment freed the pledge on 79.5 million Thyrocare shares.
The business
- API Holdings operates PharmEasy (online pharmacy), Thyrocare (diagnostics), Ascent (medicine distributor), and Aknamed (hospital supply chain).
- PharmEasy offers medicine delivery, lab tests, doctor consultations, vaccinations, elder care, nursing, and AI-powered physiotherapy.
- Its AI physiotherapy platform uses smartphone camera for posture analysis and covers 250+ conditions with 60+ physiotherapists.
- PharmEasy lab tests are powered by Thyrocare.
- The B2B business (including Ascent) had Q1 FY27 revenue of ₹1,005.6 crore, up 8% YoY.
- Thyrocare processed 55.2 million tests in Q1 FY27, up 28% YoY.
The founders
- Co-founded PharmEasy.
- Said the biggest mistake was not using available capital to repay debt, instead deploying it for growth and secondary share buyback.
- Co-founded PharmEasy.
- Co-founded PharmEasy.
Who put in money
- Citigroup buyer — Global investment bank.
- Morgan Stanley buyer — Global financial services firm.
- HSBC Mutual Fund buyer — Asset management arm of HSBC.
- Prosus existing — Global consumer internet group and investor.
- Temasek existing — Singaporean state-owned investment company.
- TPG Growth existing — Growth equity arm of TPG Capital.
- CDPQ existing — Canadian pension fund manager.
- 360 One existing — Indian wealth and asset management firm.
- Ranjan Pai's MEMG existing — Largest shareholder in API Holdings with estimated stake >12%.
In numbers
₹1,050 croreDebt repaid · 2026
1,57,69,696Thyrocare shares sold · 2026
~₹986 croreSale proceeds · 2026
₹624Sale price per share · 2026
51.02%Promoter holding after sale · 2026
~₹1,650 croreTotal from two stake sales · 2026
₹240 croreThyrocare Q1 FY27 revenue · 2026
₹51 croreThyrocare Q1 FY27 PAT · 2026
₹77 croreThyrocare Q1 FY27 EBITDA · 2026
₹1,754 croreAPI Holdings Q1 FY27 revenue · 2026
₹29.6 croreAPI Holdings Q1 FY27 loss (ex-Esop) · 2026
₹39.3 croreAPI Holdings Q1 FY27 EBITDA · 2026
₹348 crorePharmEasy Q1 FY27 revenue · 2026
₹17 crorePharmEasy Q1 FY27 EBITDA loss · 2026
₹5,980 croreAPI Holdings FY25 revenue · 2025
₹1,572 croreAPI Holdings FY25 net loss · 2025
$5.6 billionPharmEasy valuation 2021
~$700 millionPharmEasy valuation 2024
Earlier rounds
- 2024 · rights issue · ₹3,500 crore
- 2025 · debentures · ₹1,700 crore
Up against
Tata 1mgReliance-owned NetmedsApollo 247Fix HealthPhyt.healthFlexifyMePractoMediBuddy
Words to know
- Block deal
- A large sale of shares arranged privately between a seller and a few buyers, often at a discount to the market price.
- Promoter holding
- The percentage of a company's shares owned by its founders or founding group.
- Pledge
- Shares given as collateral for a loan; if the loan is not repaid, the lender can sell the shares.
- Reverse merger
- A private company merges into a public company, allowing the private company to become publicly traded without an IPO.
The numbers around it
Healthcare & Life Sciences in August 2026: 10 rounds with a disclosed amount, $139 million in all; the biggest was Biodeal Pharmaceuticals (₹385 crore). Every sector this year →
Other articles talking about it
UnlistedZone ↗The Economic Times ↗Fortune India ↗Fortune India ↗CNBC TV18 ↗The Economic Times ↗The Economic Times ↗CNBC-TV18 ↗The Economic Times ↗Inc42 ↗
Terms in this story
- Profitability: A path to profitability is the plan and evidence that a startup will earn more than it spends. In India the usual order is contribution positive, then EBITDA positive, then net profit and positive cash flow. Each step is a different test, so claims of profit need the definition.
- Profitability: Profitable can mean five different things in a startup headline: profit after tax, positive EBITDA, positive adjusted EBITDA, positive cash flow or profit on each order. Only the first is a profit in the full accounting sense. Always check which one a story means.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
Everything on PharmEasy → · All startup news on 16 August 2026 →
Is this PharmEasy? Get your “Featured on StopDown” badge →